Good News! AIDS Vaccine Passes Key Early Test

Scientists have made significant progress in developing a vaccine to mitigate the spread and potency of AIDS in the human society.
Scientists have announced that a candidate AIDS vaccine which triggered an immune response in humans and shielded monkeys from infection, has passed its key early test.

The AIDS vaccine which is an output of a 40-year quest for an AIDS cure, proved to be safe in humans and has now advanced to the next phase of the pre-approval trial process. It will now be tested in 2,600 women in southern Africa to see whether it prevents HIV infection.

Though the trials so far has been encouraging, the research team and outside experts warn there are no guarantees it will actually work in the next trial phase dubbed HVTN705 or “Imbokodo” — the isiZulu word for “rock”.

“Although these data are promising, we need to remain cautious,” study leader Dan Barouch, a Harvard Medical School professor, told AFP.

Just because it protected two-thirds of monkeys in a lab trial doesn’t mean the drug will protect humans, “and thus we need to await the results of the… study before we know whether or not this vaccine will protect humans against HIV infection,” he said.

The team also disclosed that the results of the Imbokodo trial are expected in 2021/22.

“This is only the fifth HIV vaccine concept that will be tested for efficacy in humans in the 35+ year history of the global HIV epidemic,” added Barouch.

Only one so far, RV144, yielded some protection. RV144 was reported in 2009 to reduce the risk of HIV infection among 16,000 Thai volunteers by 31.2 percent — deemed insufficient for the drug to be pursued.

For the latest study, published in The Lancet medical journal, Barouch and a team tested the candidate drug on 393 healthy, HIV-free adults aged 18 to 50 in east Africa, South Africa, Thailand, and the United States. The participants were randomly given one of seven vaccine combinations or a placebo “dummy” alternative. They received four shots each over 48 weeks.

The study used so-called “mosaic” vaccine combinations. These combine pieces of different HIV virus types to elicit an immune response — when the body attacks intruder germs — against virus strains from different regions of the world.

The vaccine “induced robust (high levels of) immune responses in humans,” said Barouch. The tests also showed the vaccine was safe. Five participants reported side-effects such as stomach pain and diarrhoea, dizziness, or back pain.

In a separate study, the same vaccine offered complete protection from infection in two-thirds of 72 trial monkeys each given six injections with an HIV-like virus.

An estimated 37 million people live with HIV/AIDS, according to the World Health Organization. There are about 1.8 million new infections and a million deaths every year. Almost 80 million people are estimated to have been infected since the virus was first diagnosed in the early 1980s. About 35 million have died.

Download Edujandon.com News App QR-Code

Edujandon.com - 24/7 News Upda

Developer: Edujandon Enterprises

Price: Free